BioMarin Announces Updated Strategy for ROCTAVIAN to Focus on US, Germany, and Italy
BMRN Focuses on Key Markets for Hemophilia A Treatment
New Strategy Aims to Improve Profitability and Patient Access
Novato, CA – March 8, 2023 – BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced an updated strategy for ROCTAVIAN® (valoctocogene roxaparvovec), its one-time, single-dose gene therapy for adults with severe hemophilia A.
The new strategy will focus on the US, Germany, and Italy, where ROCTAVIAN is currently approved. BioMarin will discontinue commercial activities in other countries to prioritize these key markets and improve the efficiency of its operations.
This strategic shift is expected to reduce operating expenses significantly, with the goal of achieving ROCTAVIAN profitability by 2024. BioMarin remains committed to providing access to ROCTAVIAN for patients in the US, Germany, and Italy, and will continue to invest in research and development to advance gene therapies for hemophilia.
In conclusion, BioMarin's updated strategy for ROCTAVIAN is a bold move that aims to improve the profitability and accessibility of this groundbreaking gene therapy. By focusing on key markets and streamlining operations, BioMarin is positioning ROCTAVIAN for long-term success and continued innovation in the treatment of hemophilia.
Komentar